Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
Not Applicable
Completed
- Conditions
- Lymphoma, Non-HodgkinHodgkin Disease
- Registration Number
- NCT00534989
- Brief Summary
Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Patients with NHL and HD undergoing HDC and ASCT
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Prognosis overall
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie FDG PET's ability to predict residual disease in NHL and HD patients post-HDC and ASCT?
How does FDG PET compare to standard imaging techniques in predicting relapse after high-dose chemotherapy and autologous stem cell transplantation for NHL and HD?
Which biomarkers are associated with favorable outcomes in NHL and HD patients undergoing FDG PET assessment prior to HDC and ASCT?
What adverse events are commonly observed in NHL and HD patients treated with high-dose chemotherapy and ASCT, and how are they managed in conjunction with FDG PET monitoring?
Are there combination therapies or alternative imaging modalities that enhance FDG PET's predictive value for residual disease in lymphoma patients undergoing HDC and ASCT?